Interpace Biosciences fully repays BroadOak term loan early

Interpace Biosciences, Inc. reported that on December 3, 2025 it fully repaid its outstanding term loan facility with BroadOak Capital Partners before the loan’s scheduled maturity.

Accepted by SEC EDGAR 12/03/2025 - 04:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Interpace Biosciences, Inc. reported that on December 3, 2025 it fully repaid its outstanding term loan facility with BroadOak Capital Partners before the loan’s scheduled maturity. This means the company has cleared that specific debt obligation earlier than required, which can simplify its capital structure and reduce future interest payments. The update was shared through a press release attached as an exhibit, providing more detail on the repayment and its context for the business.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Interpace Biosciences (IDXG) announce on December 3, 2025?

Interpace Biosciences announced that it has fully repaid its outstanding term loan facility with BroadOak Capital Partners before the loan’s maturity date.

Which loan did Interpace Biosciences (IDXG) repay early?

The company repaid its outstanding term loan facility with BroadOak Capital Partners in full.

Did Interpace Biosciences (IDXG) repay the BroadOak term loan before maturity?

Yes. Interpace Biosciences stated that the term loan facility with BroadOak Capital Partners was fully repaid prior to its maturity date.

How did Interpace Biosciences (IDXG) communicate the debt repayment?

The company issued a press release on December 3, 2025, which is included as Exhibit 99.1 to the report.

Where can investors find more details on Interpace Biosciences’ (IDXG) loan repayment?

Additional details are provided in the press release dated December 3, 2025, filed as Exhibit 99.1 to the report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001054102 0001054102 2025-12-03 2025-12-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 3, 2025

INTERPACE BIOSCIENCES, INC.

(Exact name of Registrant as specified in its charter)

Delaware		000-24249		22-2919486
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Waterview Plaza, Suite 310, 2001 Route 46

Parsippany, NJ 07054

(Address, including zip code, of Principal Executive Offices)

(855) 776-6419

Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On December 3, 2025, Interpace Biosciences, Inc. issued a press release announcing that it has fully repaid its outstanding term loan facility with BroadOak Capital Partners prior to the facility’s maturity date. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated December 3, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INTERPACE BIOSCIENCES, INC.
	By:	/s/ Thomas W. Burnell
	Name:	Thomas W. Burnell
	Title:	President and Chief Executive Officer

Date: December 3, 2025